Company profile

Chia Tai Tianqing Pharmaceutical Group

Diversified pharma

Privately held: no public share price · China

Assets

(11 total)
11Total Assets
0Approved
6Phase 3 / Filed
5Phase 1–2 / Early
6Diseases
Quick filter:
Showing 11 of 11 assets
Target & Modality
Anlotinib
Phase 3
VEGFR1/2/3, FGFR1/2/3, PDGFR-α, c-KitSmall molecule
Non-Small Cell Lung Cancer
Benmelstobart
Phase 3
PD-L1Small molecule
Non-Small Cell Lung Cancer
Culmerciclib
Phase 3
CDK2/CDK4/CDK6 · CDK2/4/6/CDK4Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
TQ-B3139No recent activity
Phase 3
ALK and c-MetSmall molecule
Non-Small Cell Lung Cancer
TQB2934
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
TQC3721
Phase 3
PDE3/PDE4Small molecule
Chronic Obstructive Pulmonary Disease
TQC3927
Phase 2
Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
TQH2929
Phase 2
Undisclosed / early pipelineMonoclonal antibody
Psoriasis
TQB3455
Phase 1
IDH2
Acute Myeloid Leukemia
TQB3602No recent activity
Phase 1
ProteasomeSmall molecule
Multiple Myeloma
TQB3820
Phase 1
Cereblon E3 ubiquitin-ligaseSmall molecule
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.